Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial

被引：0
|
作者：
Qiang Zhou
Zhiqiang Wang
Heming Wang
Zhidong Chen
Xiaoyi Li
Xiangrong Dai
Yong Zhang
Xiaohui Yu
Renpeng Zhou
Wei Hu
机构：
[1] The Second Hospital of Anhui Medical University,Department of Laboratory Medicine
[2] The Second Hospital of Anhui Medical University,Department of Clinical Pharmacology
[3] Zhujiang Hospital,Clinical Research Centre
[4] Southern Medical University,undefined
[5] The Zhaoke Pharmaceutical Co.,undefined
[6] Ltd,undefined
来源：
American Journal of Cardiovascular Drugs | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：101 / 112
页数：11
相关论文
共 50 条
  • [41] Safety and tolerability of subcutaneous PTHrP(1–36) in healthy human volunteers: a dose escalation study
    Mara J. Horwitz
    Mary Beth Tedesco
    Susan M. Sereika
    Adolfo Garcia-Ocaña
    Alessandro Bisello
    Bruce W. Hollis
    Caren Gundberg
    Andrew F. Stewart
    Osteoporosis International, 2006, 17 : 225 - 230
  • [42] Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
    Kyriakos P. Papadopoulos
    Eytan Ben-Ami
    Amita Patnaik
    Denise Trone
    Jianke Li
    George D. Demetri
    BMC Cancer, 18
  • [43] Phase I dose-escalation oncology trials with sequential multiple schedules
    Burak Kürsad Günhan
    Sebastian Weber
    Abdelkader Seroutou
    Tim Friede
    BMC Medical Research Methodology, 21
  • [44] Phase I dose-escalation oncology trials with sequential multiple schedules
    Guenhan, Burak Kuersad
    Weber, Sebastian
    Seroutou, Abdelkader
    Friede, Tim
    BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)
  • [45] Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
    Durand, Nisha C.
    Kim, H. G.
    Patel, Vishal N.
    Turnbull, Marion T.
    Siegel, Jason L.
    Hodge, David O.
    Tawk, Rabih G.
    Meschia, James F.
    Freeman, W. David
    Zubair, Abba C.
    NEUROCRITICAL CARE, 2024, 41 (01) : 59 - 69
  • [46] A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers
    Hu, Yue
    Zhang, Hong
    Li, Xiaojiao
    Mai, Jiajia
    Yang, Lizhi
    Yan, Jie
    Li, Ying
    Sun, Jingchao
    Xu, Wenjie
    He, Shiying
    Li, Jinfeng
    Wu, Min
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (09) : 977 - 985
  • [47] A Phase I Dose-Escalation Trial of Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
    Abramson, Jeremy S.
    Takvorian, Tak
    Jacobsen, Eric D.
    Brown, Jennifer R.
    Barnes, Jeffrey A.
    Feng, Yang
    Neuberg, Donna
    Hochberg, Ephraim P.
    BLOOD, 2010, 116 (21) : 740 - 740
  • [48] Multiple rising doses of oral BI 1358894 in healthy male volunteers: a phase I study investigating safety, tolerability and pharmacokinetics
    Goettel, M.
    Fuertig, R.
    Wiebe, S.
    Herich, L.
    Sharma, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S254 - S255
  • [49] Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
    Papadopoulos, Kyriakos P.
    Ben-Ami, Eytan
    Patnaik, Amita
    Trone, Denise
    Li, Jianke
    Demetri, George D.
    BMC CANCER, 2018, 18
  • [50] Safety and immunogenicity in a phase I dose-escalation BPV-1VLP vaccine trial in horses
    Kirnbauer, R.
    Brandt, S.
    Shafti-Keramat, S.
    Hainisch, E. K.
    WIENER KLINISCHE WOCHENSCHRIFT, 2008, 120 : 17 - 18
12345